옵션 체인은 다양한 행사가격과 만기일에 대한 Immuneering의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Immuneering에 대한 시장 심리를 평가합니다..

Immuneering (NASDAQ:IMRX) 주식, 옵션 체인

IMMUNEERING CORP - CLASS A

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Immuneering Corporation - Class A Common Stock

Immuneering Corp

Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) has outperformed the market over the past 15 years by 9.74% on an annualized basis producing an average annual return of 21.8%. Currently, Intuit has a market capitalization of $187.55 billion. 
Buying $1000 In INTU: If an investor had bought $1000 of INTU stock 15 years ago, it would be worth $19,433.95 today based on a price of $670.86 for INTU at the time of writing.
<h3>Intuit's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747690227_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

INTU

Here's How Much You Would Have Made Owning Intuit Stock In The Last 15 Years

GIPR

Trading Halt: Halt status updated at 5:30:00 PM ET: Quotation Resumption: News and Resumption Times

General

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Qualigen Therapeutics Receives Notice Of Deficiency From Nasdaq Related To Delayed Filing Of Quarterly Report On Form 10-Q

TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. This is a 78.95 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $42.14 million which beat the analyst consensus estimate of $41.70 million by 1.06 percent. This is a 23.63 percent increase over sales of $34.09 million the same period last year.

Earnings

Earnings Beats

TATT

TAT Techs Q1 EPS $0.34 Beats $0.31 Estimate, Sales $42.14M Beat $41.70M Estimate

WIIM

PEGA

Pegasystems shares are trading higher after it was announced that the company will join the S&P Midcap 400 On May 22, 2025.

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250519-1478064/1478064_4jwn.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250519-1478064/1478064_4jwn.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250519-1478064/1478064_4jwn.pdf</a>

Pegasystems Will Replace Nordstrom In The S&P Midcap 400 Effective Prior To The Opening Of Trading On May 22, 2025

It's no secret that real estate brokerage and mortgage origination service provider Redfin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) is struggling. Although its year-to-date performance is impressive, RDFN stock is down 66% in the trailing five years. The equity is also a fraction of its February 2021 peak — a victim of soaring inflation, high interest rates and now, <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45263291/fed-keeps-rates-steady-warns-of-rising-uncertainty-about-the-economic-outlook">broader economic uncertainty</a>. Still, with so much bad news baked in, any positive developments could have an exponentially strong effect.
Fundamentally, analysts refer to the above concept as value compression. After a severe decline in a publicly traded security, expectations for the underlying company are deflated. Subsequently, a small positive catalyst can cause a snapback rally. For RDFN stock, the main catalysts revolve around the benchmark interest rate and global trade policies. Even better, there are legitimate reasons for optimism.
Regarding interest rates, the Federal Reserve is keeping a watchful eye on core economic metrics. Should conditions justify a more accommodative policy, it's possible — perhaps likely — that the Fed will respond with a dovish approach. A step toward lower rates could accelerate sentiment in RDFN stock, given how deflated it already is.
As for trade policies, President Donald Trump's tariffs have created uncertainty in the housing market, particularly in the realm of implied <a href="https://www.benzinga.com/news/econ-s/25/04/44795415/trumps-tariffs-could-send-rents-higher-economist-warns">higher building material costs</a>. At the same time, the administration appears to be making progress, recently striking a <a href="https://www.benzinga.com/media/25/05/45481159/donald-trump-offers-to-visit-xi-jinping-in-beijing-calls-us-china-ties-important-after-striking-temporary-trade-truce">temporary trade truce with China</a>.
Put another way, it's possible that the bulk of the bad news is in the rearview mirror. Therefore, the few inches of momentum that the economy is able to generate could spark outsized returns for Redfin.
<h2 class="wp-block-heading">Market Breadth Data Signals Optimism For RDFN Stock</h2>
Although the narrative for Redfin's business may finally have reached a turning point, traders seeking to extract alpha from RDFN stock need far more reliable clues than deciphering talking points. It's here where market breadth data — essentially analyzing the accumulation and distribution of demand — becomes invaluable.
In the past 10 weeks, RDFN stock printed a "7-3-U" sequence: seven up weeks mixed with three down weeks, with a net positive trajectory across the period. This bullish-dominated sequence has materialized 53 times since Redfin's initial public offering. Significantly, in 62.26% of cases, the following week's price action results in upside, with a median return of 4.86%.
To put this framework in colloquial terms, the deck has become hot, thus incentivizing a bullish wager. In any given week, the chance that a long position in RDFN stock will be profitable is only 48.8%. Stated differently, RDFN natively features a negative bias. Therefore, when traders buy Redfin options, the premiums reflect this pessimistic propensity.
However, under certain conditions, the probability of forward momentum in RDFN stock can vary significantly from the baseline probability. And that's what the 7-3-U market breadth data signals to the speculator. It's not a special indicator, per se. Rather, when this sequence appears, RDFN behaviorally transitions from a statistically poor wager (from the bull's perspective) to a favorable one.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19143026/RDFN-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-920228" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19143026/RDFN-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19143026/RDFN-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19143026/RDFN-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19143026/RDFN-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Assuming that the bulls take control of the market, RDFN stock could potentially hit $10.64 in a week or two. Speculators can then use this forecast to plot an effective options strategy.
<h2 class="wp-block-heading">Taking a Quick Swing at Redfin</h2>
Traders seeking a quick boost may consider the 10/10.50 bull call spread expiring May 30. This transaction involves buying the $10 call and simultaneously selling the $10.50 call. The proceeds from the short call partially offset the debit paid for the long call, resulting in a net debit paid of $32, the most that can be lost in the trade.
Should RDFN stock rise through the short strike price of $10.50 at expiration, the maximum reward for the aforementioned bulls spread is $18, a payout of over 56%.
What makes this trade attractive is that from a nominal perspective, the risk is quite minimal. At $32, traders can nibble at this spread with pocket change. From a probabilistic angle, the better holds an underappreciated advantage. Most of the market assumes that the bears have the statistical edge — which would be true in the average case.
However, RDFN is responding to a specific market breadth setup and that could make all the difference in this trade.
Read Next:
<a href="https://www.benzinga.com/top-stories/25/05/45476901/political-turmoil-bmy-stock-contrarian-bull-call-spread">Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb</a>
Photo: Shutterstock

Equities

Long Ideas

Options

RDFN

Options Corner: Redfin's Value Compression Sets The Stage For A Bullish Bounce Back

VTAK

Catheter Precision Enters At Market Offering Agreement With Ladenburg Thalmann & Co; May Sell Up To $1.3M In Common Stock

Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has outperformed the market over the past 10 years by 26.43% on an annualized basis producing an average annual return of 37.37%. Currently, Strategy has a market capitalization of $114.25 billion. 
Buying $1000 In MSTR: If an investor had bought $1000 of MSTR stock 10 years ago, it would be worth $23,926.15 today based on a price of $413.01 for MSTR at the time of writing.
<h3>Strategy's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747689312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSTR

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

President Donald Trump's sweeping legislative package is, as expected, divisive. Republicans are pitching it as &#8220;One, Big Beautiful Bill.&#8221; Democrats are <a href="https://www.youtube.com/watch?v=D2cwPUb21IE">calling it</a> &#8220;one big beautiful betrayal.&#8221; Here's a look at some of the bill&#8217;s <a href="https://www.benzinga.com/personal-finance/25/05/45485150/the-one-big-beautiful-bill-would-create-maga-savings-accounts-with-a-1000-gift-from-the-government-at-birth">key elements</a>.&nbsp;
The Winners: The bill seeks to extend The Tax Cuts and Jobs Act (TCJA) of 2017. That means the expiring provisions that benefit high-income and wealthy earners would be permanent.
It also seeks to eliminate federal taxes on tips and overtime pay, fulfilling some of Trump&#8217;s campaign promises.&nbsp;
The tax breaks would reduce revenue by $4.9 trillion over the decade, but increase spending on military, defense and border security. 
So, if legislators sign the bill into law, major U.S. defense contractors like RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) could benefit from increased defense spending.&nbsp;
Other companies exposed to the defense sector including Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and Booz Allen Hamilton Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) could also benefit from increased military and defense spending.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45499101/big-short-legend-michael-burry-bets-big-on-lipstick-index-is-he-bracing-for-a-recession?utm_source=article">&#8216;Big Short&#8217; Legend Michael Burry Bets Big On Lipstick Index: Is He Bracing For A Recession?</a>
The Losers: The cost of the tax bill will be partially balanced with new taxes on private university endowments and significant cuts to programs like Medicaid.
Stocks of major Medicaid managed care organizations could be vulnerable to enrollment volatility and premium pricing challenges if the changes are approved. Investors would be wise to monitor UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) and Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) as the bill moves through Congress. 
Low-income Americans who rely on food assistance should also take note. House Republicans are proposing major changes to the Supplemental Nutrition Assistance Program, or SNAP. The program aids over 42 million Americans. The bill would shift 5% of benefit costs and 75% of administrative costs to states, up from the current 50% share for administration only. It also seeks to expand work requirements to recipients up to age 64.
Democrats have criticized the move as harmful to families, while Republicans say it promotes work and cuts waste. The House Agriculture Committee has already <a href="https://www.politico.com/live-updates/2025/05/14/congress/house-agriculture-committee-approves-300-billion-in-nutrition-spending-cuts-00350900">approved</a> $300 million in SNAP cuts to help fund tax breaks.
If the<a href="https://www.benzinga.com/general/health-care/25/05/45431505/gop-tax-bill-breaks-trumps-social-security-tax-pledge-still-hits-25-million-seniors-while-elon-musks-stock-wealth-skirts-fica"> legislative package</a> is passed, it would also be the end of many clean energy initiatives and key tax credits and would impose new fees on electric vehicles. These changes could slow the growth of the clean energy sector and make electric vehicles and renewables less competitive compared to traditional energy sources.&nbsp;
Clean energy stocks including Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) and Sunrun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were all sharply lower on Monday as investors digested the potential effects on the industry.&nbsp;
The 1,116-page bill also wouldn&#8217;t quell fears about America&#8217;s public debt, which currently stands at $36 trillion. According to the nonpartisan watchdog group, the Committee for a Responsible Federal Budget, the bill <a href="https://www.crfb.org/blogs/adding-house-reconciliation-bill">adds</a> approximately $3.3 trillion to the national debt over the next ten years.
What's Next: After advancing out of the House Budget Committee in a rare Sunday meeting by a narrow 17-16 vote, Trump&#8217;s &#8220;One Big, Beautiful Bill&#8221; faces several<a href="https://www.benzinga.com/25/05/45481745/donald-trump-backed-gop-bill-seeks-to-ban-states-from-regulating-ai-for-10-years-critics-warn-its-federal-overreach-that-could-backfire"> key steps</a> before it can become law.
The next stop is the House Rules Committee, which will meet midweek to set the terms for floor debate, consider possible amendments, and make any necessary last-minute adjustments to the bill before it heads to a full vote on the House floor. 
If the bill passes the House, it will move to the Senate where it may face additional challenges, as Republican senators are also seeking changes that could complicate final passage.
Further changes to the bill are possible as leaders work to secure enough support from both conservative and moderate factions.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Government

Large Cap

Regulations

Health Care

Politics

Movers

Tech

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ENPH

FSLR

Trump's 'Big Beautiful Bill' Advances: Here's Who Wins And Loses

<h3>Gainers</h3>
<ul>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares rose 10.3% to $1.28 during Monday's after-market session. The market value of their outstanding shares is at $260.5 million. </li>
<li>Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) shares increased by 6.97% to $0.89. The company's market cap stands at $40.8 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock moved upwards by 6.61% to $2.9. The company's market cap stands at $829.9 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) stock moved upwards by 6.24% to $0.85. The company's market cap stands at $8.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) shares increased by 6.2% to $17.8. </li>
<li>Kirkland's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) shares moved upwards by 6.03% to $1.23. The market value of their outstanding shares is at $27.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares declined by 8.8% to $0.31 during Monday's after-market session. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares decreased by 6.78% to $1.1. The market value of their outstanding shares is at $9.4 million. </li>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares declined by 5.83% to $0.19. The market value of their outstanding shares is at $20.9 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock decreased by 5.22% to $0.4. The market value of their outstanding shares is at $2.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) stock decreased by 4.95% to $12.3. The company's market cap stands at $786.0 million. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) stock decreased by 4.91% to $0.97. The company's market cap stands at $29.9 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYRO

CENN

GORV

KIRK

LOBO

LVWR

MULN

NDLS

NWTN

PTLO

QVCGP

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 26.7% to $0.29 during Monday's after-market session. The company's market cap stands at $5.2 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 15.38% to $0.01. </li>
<li>Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) stock moved upwards by 13.5% to $2.69. The company's market cap stands at $97.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 8.33% to $0.01. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares increased by 7.33% to $1.61. The company's market cap stands at $7.9 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) stock moved upwards by 6.29% to $0.73. The market value of their outstanding shares is at $118.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 26.3% to $0.24 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares declined by 14.63% to $2.2. The market value of their outstanding shares is at $5.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares fell 13.47% to $2.7. The market value of their outstanding shares is at $88.2 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock declined by 10.64% to $0.22. The company's market cap stands at $10.9 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 8.42% to $0.38. The market value of their outstanding shares is at $6.1 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 6.26% to $1.2. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

ARMP

ASBP

BDRX

BIAF

CBUS

EKSO

HCTI

LIPO

MSPR

NMRA

PLRZ

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares rose 32.8% to $0.2 during Monday's after-market session. The company's market cap stands at $29.7 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock moved upwards by 6.54% to $0.44. The market value of their outstanding shares is at $3.1 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock moved upwards by 6.53% to $5.02. The market value of their outstanding shares is at $62.7 million. The company's, FY earnings came out 4 days ago. </li>
<li>Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) stock increased by 6.53% to $1.58. The market value of their outstanding shares is at $48.5 million. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock moved upwards by 5.26% to $0.8. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) stock increased by 5.07% to $85.3. The company's market cap stands at $794.0 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) stock declined by 5.3% to $0.3 during Monday's after-market session. The market value of their outstanding shares is at $7.2 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares decreased by 5.04% to $0.3. The market value of their outstanding shares is at $43.4 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock declined by 5.03% to $1.13. The company's market cap stands at $24.2 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) stock fell 5.0% to $0.66. The company's market cap stands at $20.5 million. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) shares fell 4.98% to $0.55. The company's market cap stands at $3.3 million. </li>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares declined by 4.83% to $6.31. The market value of their outstanding shares is at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXG

BIYA

FTEK

HOVR

LICN

NCEW

PSIG

SCWO

SGBX

TRNS

XPON

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) shares rose 6.0% to $1.51 during Monday's after-market session. The company's market cap stands at $74.1 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) stock increased by 4.96% to $19.67. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) shares rose 4.77% to $25.45. The market value of their outstanding shares is at $324.4 million. </li>
<li>SmartKem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) stock moved upwards by 4.58% to $1.14. The market value of their outstanding shares is at $4.1 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) stock moved upwards by 4.51% to $1.39. The market value of their outstanding shares is at $173.8 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>BigCommerce Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>) shares increased by 4.32% to $5.3. The market value of their outstanding shares is at $424.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock fell 17.0% to $1.95 during Monday's after-market session. The market value of their outstanding shares is at $50.3 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock declined by 6.57% to $1.28. </li>
<li>Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares fell 4.59% to $6.03. The company's market cap stands at $5.9 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) shares decreased by 4.31% to $2.0. The company's market cap stands at $29.0 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares decreased by 4.27% to $0.23. The company's market cap stands at $14.7 million. </li>
<li>AXT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXTI#NASDAQ">AXTI</a>) shares declined by 4.17% to $1.38. The company's market cap stands at $62.9 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARQQ

AXTI

BIGC

CPSH

LWLG

Penguin Solutions, Inc. - Ordinary Shares

PENG

SMTK

SVRE

TDTH

VERB

WRAP

12 Information Technology Stocks Moving In Monday's After-Market Session

PPTA

Perpetua Resources Receives Final Federal Permit From The USACE For Its Stibnite Gold Project

Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) sees Q2 sales of $76.000 million-$83.000 million vs $86.90 million analyst estimate.

Guidance

YALA

Yalla Group Sees Q2 Sales $76.000M-$83.000M vs $86.90M Est

Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) reported quarterly earnings of $0.22 per share. This is a 10 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $83.88 million which beat the analyst consensus estimate of $81.80 million by 2.55 percent. This is a 6.54 percent increase over sales of $78.73 million the same period last year.

Yalla Group Q1 Adj. EPS $0.22 Up From $0.20 YoY, Sales $83.88M Beat $81.80M Estimate

16 analysts have expressed a variety of opinions on American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $89.25, a high estimate of $98.00, and a low estimate of $81.00. Surpassing the previous average price target of $85.62, the current average has increased by 4.24%.
<img src="https://www.benzinga.com/files/images/story/2025/1747688468_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of American International Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$81.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$81.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$89.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$83.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to American International Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American International Gr compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of American International Gr's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AIG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on American International Gr analyst ratings.</a>
<h2>All You Need to Know About American International Gr</h2>
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.
<h3>A Deep Dive into American International Gr's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: American International Gr displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 0.01%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.66%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.43%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: American International Gr's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: American International Gr In The Eyes Of 16 Experts

In the preceding three months, 10 analysts have released ratings for Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.3, a high estimate of $90.00, and a low estimate of $45.00. This current average has decreased by 26.14% from the previous average price target of $85.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1747688458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Allegiant Travel. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$50.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$90.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Allegiant Travel. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allegiant Travel compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Allegiant Travel's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allegiant Travel analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Allegiant Travel's Background</h2>
Allegiant Travel Co is a leisure travel company focused on providing travel and leisure services and products to residents of under-served cities in the United States. It operates a low-cost, low utilization passenger airline marketed to leisure travelers in under-served cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third-party services and products. In addition, it provides air transportation under fixed-fee flight arrangements. In connection with its leisure travel focus, the company has opened Sunseeker Resort Charlotte Harbor, equipped with several guestrooms and food and beverage outlets. The company's operating segments are the Airline, which generates maximum revenue, and Sunseeker Resort.
<h3>A Deep Dive into Allegiant Travel's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Allegiant Travel displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 6.5%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Allegiant Travel's net margin is impressive, surpassing industry averages. With a net margin of 4.47%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Allegiant Travel's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Allegiant Travel's ROA stands out, surpassing industry averages. With an impressive ROA of 0.7%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.88, Allegiant Travel adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGT

A Glimpse Into The Expert Outlook On Allegiant Travel Through 10 Analysts

In the last three months, 4 analysts have published ratings on NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for NetEase, presenting an average target of $118.0, a high estimate of $135.00, and a low estimate of $104.00. This upward trend is evident, with the current average reflecting a 14.84% increase from the previous average price target of $102.75.
<img src="https://www.benzinga.com/files/images/story/2025/1747688449_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of NetEase among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Chen</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NetEase. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NetEase compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for NetEase's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NetEase's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NTES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NetEase analyst ratings.</a>
<h2>Discovering NetEase: A Closer Look</h2>
Founded in the late 1990s as an internet portal, NetEase has transformed into a leading force in the second-largest online game company gaming in China. While its initial success was built upon the massively multiplayer online role-playing game Fantasy Westward Journey, NetEase has expanded its portfolio with captivating franchises that resonate with both domestic and international players. Over the past decade, the company has created titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which maintain significant player bases today. Beyond in-house development, the company also collaborates with likes of Microsoft and Marvel to create and publish games based on renowned IPs, including World of Warcraft, Diablo Immortal, and Marvel Rivals.
<h3>NetEase's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: NetEase's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 7.36%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 35.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): NetEase's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 7.29%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.19%, the company showcases effective utilization of assets.
Debt Management: NetEase's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTES

A Glimpse Into The Expert Outlook On NetEase Through 4 Analysts

Opinion

Press Releases

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Management

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Corporation Announces Grant of Inducement Award

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Comments

Immuneering

Immuneering (IMRX) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌